Jaguar8 commented on a stock · Sep 16, 2024 20:15

NEWS

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease

Coya Therapeutics (NASDAQ: COYA) announces promising results for COYA 302, a subcutaneously administered anti-inflammatory biologic, in a preclinical Parkinson's disease (PD) mouse model. The study shows that COYA 302significantly reduces neuroinflammation in key brain regions affected by PD, including:
Decreased microglial activation in the nigrostriatal pathway
Reduced astrocyte numbers and activation (astrogliosis)
These findings suggest that COYA 302can directly modulate brain inflammation when administered peripherally, potentially offering a new therapeutic approach for PD and other neurodegenerative diseases like Alzheimer's and Frontotemporal Dementia. The company plans to present or publish these results in a peer-reviewed setting.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

6522 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

6063Followers

70Following

65KVisitors